InspireMD, Inc. (NSPR)

NASDAQ: NSPR · Real-Time Price · USD
2.410
+0.020 (0.84%)
At close: Aug 8, 2025, 4:00 PM
2.391
-0.019 (-0.80%)
After-hours: Aug 8, 2025, 5:27 PM EDT
0.84%
Market Cap100.96M
Revenue (ttm)7.07M
Net Income (ttm)-41.38M
Shares Out 41.72M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume49,020
Open2.440
Previous Close2.390
Day's Range2.370 - 2.440
52-Week Range1.990 - 3.798
Beta0.60
AnalystsStrong Buy
Price Target4.50 (+86.72%)
Earnings DateAug 5, 2025

About SPLK

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. ... [Read more]

Sector Healthcare
Founded 2005
Employees 86
Stock Exchange NASDAQ
Ticker Symbol NSPR
Full Company Profile

Financial Performance

In 2024, InspireMD's revenue was $7.01 million, an increase of 12.96% compared to the previous year's $6.21 million. Losses were -$32.01 million, 60.7% more than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for NSPR stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 86.72% from the latest price.

Price Target
$4.5
(86.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

InspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Marvin L. Slosman - President, CEO & Director Michael A.

5 days ago - Seeking Alpha

InspireMD Reports Second Quarter 2025 Financial Results

--- Management to host investor conference call today, August 5 th , at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid st...

5 days ago - GlobeNewsWire

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...

10 days ago - GlobeNewsWire

InspireMD Announces Combined Financings of $58 Million

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announce...

10 days ago - GlobeNewsWire

InspireMD to Announce Second Quarter 2025 Financial Results

MIAMI, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release it...

19 days ago - GlobeNewsWire

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch...

4 weeks ago - GlobeNewsWire

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. ...

6 weeks ago - GlobeNewsWire

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE M...

2 months ago - GlobeNewsWire

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today...

2 months ago - GlobeNewsWire

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

InspireMD, Inc. (NASDAQ:NSPR) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Webb Campbell – Gilmartin Group LLC Marvin Slosman – Chief Executive Officer Craig Shore – C...

3 months ago - Seeking Alpha

InspireMD Reports First Quarter 2025 Financial Results

Management to host investor conference call today, May 9th, at 8:30am ET Management to host investor conference call today, May 9th, at 8:30am ET

3 months ago - GlobeNewsWire

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, toda...

3 months ago - GlobeNewsWire

InspireMD to Announce First Quarter 2025 Financial Results

MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke...

3 months ago - GlobeNewsWire

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Commit...

4 months ago - GlobeNewsWire

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, toda...

4 months ago - GlobeNewsWire

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

NSPR (NASDAQ:NSPR) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Webb Campbell - IR, Gilmartin Group Confe...

5 months ago - Seeking Alpha

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, toda...

5 months ago - GlobeNewsWire

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke,...

5 months ago - GlobeNewsWire

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, ...

6 months ago - GlobeNewsWire

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions Study represents a significant step ...

8 months ago - GlobeNewsWire

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of...

9 months ago - GlobeNewsWire

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

InspireMD, Inc. (NASDAQ:NSPR) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Chuck Padala - IR, Life Advisors Marvin Slosman - CEO Craig Shore - CFO Shane Gleason ...

9 months ago - Seeking Alpha

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment ...

10 months ago - GlobeNewsWire

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

MIAMI, Oct. 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food...

10 months ago - GlobeNewsWire

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May

11 months ago - GlobeNewsWire